Volume 17, Number 3—March 2011
Research
Swine Influenza Virus Antibodies in Humans, Western Europe, 2009
Table 4
Participant
age in 2009, y |
Pandemic (H1N1) 2009 (A/Luxembourg/43/2009) |
Avian-like SIV (H1N1) (A/swine/Belgium/1/98) |
Seasonal influenza (H1N1)
(A/Luxembourg/572/2008) |
|||||
Swine workers |
Controls |
Swine workers |
Controls |
Swine workers |
Controls |
|||
<40 |
22/69 (31.9;
22.1–43.6)† |
12/80 (15;
8.8–24.4) |
19/69 (27.5;
18.4–39.0) |
15/80 (18.8;
11.7–28.7) |
58/68 (85.3;
6.9–93.7) |
50/78 (64.1;
53.5–74.8) |
||
41–50 |
10/59 (16.9;
9.5–28.5) |
5/58 (8.6;
3.7–18.6) |
11/59 (18.6;
10.7–30.4) |
8/58 (13.8;
7.2–24.9) |
46/59 (78;
67.4–88.6) |
29/57 (50.9;
37.9–63.9) |
||
51–60 |
9/39 (15.3;
12.7–38.3) |
3/41 (7.3;
2.5–19.4) |
17/39 (43.6;
29.3–59.0)‡ |
8/41 (19.5;
10.2–34.0) |
37/39 (94.9;
88.0–101.8)§ |
19/41 (46.3;
31.1–61.6) |
||
>60 |
5/44 (8.6;
5.0–24.0)¶ |
3/45 (6.7;
2.3–17.9)# |
19/44 (43.2;
29.7–57.8) |
28/45 (62.2;
47.6–74.9) |
42/44 (95.5;
89.3–101.6)** |
34/45 (75.6;
63.0–88.1) |
||
18–94 (total) | 46/211 (21.8; 16.8–27.9)†† | 23/224 (10.3; 6.9–14.9)‡‡ | 66/211 (31.3; 25.4–37.8) | 59/224 (26.3; 21.0–32.5) | 183/210 (87.1; 83.0–91.9) | 132/221 (59.7; 53.2–66.0) |
*Values are no. persons/total no. persons in age groups with antibody reactivity >10 (%; 95% confidence interval). p values <0.05 cutoff for significance were calculated by using the χ2 test. SIV, swine influenza virus.
†p = 0.012, compared with controls of the same age group against pandemic (H1N1) 2009.
‡p = 0.037, compared with controls of the same age group against avian-like SIV (H1N1).
§p<0.001, compared with controls of the same age group against seasonal influenza (H1N1).
¶p = 0.002, compared with swine workers of the same age group against avian-like SIV (H1N1).
#p<0.001, compared with controls of the same age group against avian-like SIV (H1N1).
**p<0.05, compared with controls of the same age group against seasonal influenza (H1N1).
††p<0.05, compared with swine workers against avian-like SIV (H1N1).
‡‡p<0.001, compared with controls against avian-like SIV (H1N1).